The thrombogenicity of Dacron arterial grafts may lead to eventual closure, although Dacron aorto-femoral grafts rarely thrombose because of wide calibre and rapid blood flow. The less favourable outcome of Dacron grafts with narrow diameter or suboptimal flow may be improved by antithrombotic therapy during the “thrombogenic period” of graft maturation. To evaluate this period, platelet and fibrinogen kinetics using, Chromium 51 and Iodine 125 respectively, were measured pre-operation and at 3, 6 and 9 months, in 10 patients after aorto-femoral Dacron bypass. Six age-matched volunteers were simultaneously studied. Platelet survival time was reduced 8.8 to 7.4 days (p<0.01) and platelet turnover increased at 3 months post-operation compared with pre-operative levels 39 to <47/103/days. Similarly, fibrinogen T½ life was decreased 3.7 to 3.4 days and fractional catabolic rate increased at 3 months 0.27 to 0.34 (p< 0.01). These indices of thrombogenic activity returned to pre-operative levels by 9 months. We suggest that Dacron aorto-femoral grafts remain thrombogenically active for about 9 months. Where blood flow conditions are suboptimal or graft diameters are small, it may be prudent to use antithrombotic therpy to protect patency.